CXL-1427: Phase I started

Cardioxyl began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate ascending doses of 24- and 48-hour infusions of IV CXL-1427, starting at a 0.1 µg/kg/min dose, in up to 110 healthy v...